Pharmacodynamics and Active Components
The basis of Aescinum (often available under the brand name Venitan) is a phytoextract obtained from horse chestnut seeds. Its pharmacological activity is due to the presence of specific saponins and flavonoids. Interestingly, these flavonoids show a pronounced chemical structural similarity to rutosides.
The action of aescin is complex. Primarily, it acts as a classic venotonic: increases venous tone and decreases capillary permeability. By stabilizing the vascular wall, fluid exudation into the intercellular space is sharply reduced. This exact mechanism provides a potent anti-edematous effect. In addition, the drug effectively improves tissue microcirculation, relieves local inflammation, and has a mild analgesic effect, making it indispensable for acute vascular pathologies and injuries.
Clinical Indications
Due to its wide spectrum of effects (ranging from anti-inflammatory to venotonic), aescin is actively used by surgeons, phlebologists, and traumatologists. The main pool of indications is associated with impaired venous outflow and traumatic injuries.
The drug is prescribed for the following conditions:
- Chronic venous insufficiency and clinically manifest varicose veins.
- Acute manifestations of proctological diseases, specifically hemorrhoids strictly in the acute stage.
- Inflammatory venous disorders: superficial thrombophlebitis and post-thrombophlebitic syndrome.
- Traumatology profile: soft tissue contusions, ligament sprains, extensive hematomas.
- Pronounced post-traumatic or postoperative edema.
Contraindications and Risk Groups
Despite being a plant-derived drug, its safety profile requires strict adherence to instructions. The drug is strictly prohibited in case of individual hypersensitivity to horse chestnut extract or excipients.
Absolute contraindications also include:
- Severe renal failure (mandatory monitoring of renal function is required before administration).
- First trimester of pregnancy (due to the risk of negative impact in early gestation).
- Pediatric and adolescent age under 18 years.
Physicians should exercise special caution when treating patients with concomitant gastrointestinal diseases and hepatic impairment. The drug is also used with caution during lactation (breastfeeding).
Side Effect Profile
Clinical observations show that adverse reactions during aescin therapy develop quite rarely. If side effects do occur, they are usually mild and transient, not requiring immediate discontinuation of therapy.
Key categories of adverse events include:
- Gastrointestinal tract: patients may report nausea, episodes of diarrhea, dyspeptic symptoms, and moderate abdominal pain.
- Allergic reactions: skin manifestations such as pruritus, erythematous rash, or classic urticaria.
- Central nervous system: complaints of dizziness and headache are occasionally recorded.